T he clinical importance of ABO blood groups extends beyond the direct implications on transfusion and organ-transplantation compatibility. It is increasingly being recognized that individuals with non-O blood groups may be at elevated risk of venous thromboembolic events (VTEs), myocardial infarction, cerebrovascular ischemic events, and peripheral vascular disease compared with individuals with blood group O.
lack of consensus on the magnitude of this association, the extent to which it may explain population risks, and whether it affects both arterial and venous thromboembolic disease at similar magnitudes. Second, even though plausible mechanisms explaining this association have been described, it is unclear if the risk elevation among non-O blood group carriers is solely a direct effect or may also be mediated through increased risks of other diseases. Third, there is a paucity of data concerning associations with recurrent VTE events. To clarify these issues, we used a large cohort consisting of essentially all healthy blood donors after 1987 from Sweden and Denmark to investigate the effect of ABO blood group on venous thromboembolic and cardiovascular disease.
Methods

Data Sources
The SCANDAT2 (Scandinavian Donations and Transfusions) database is a computerized combined donation and transfusion register from Sweden and Denmark. After a recent update, the database includes information on >1.6 million blood donors who have donated different blood products since 1968 and 1981 in Sweden and Denmark, respectively. 10 Using unique personal national registration numbers assigned to all residents in both countries, 11, 12 the database is linked to nationwide population, death, and migration registers, thus ensuring complete follow-up of all study participants. The database is also linked to inpatient, outpatient, cause of death, and cancer registers, allowing long-term follow-up for a range of health outcomes. The ICD-9 and ICD-10 codes for primary discharge diagnoses and comorbidities are classified by the treating physician. Information on diagnosis and were obtained by linking the SCANDAT2 database to the respective patient registers. Donors with a history of venous thromboembolic or cardiovascular disease (in the national patient registers) before the first registered blood donation were excluded from the study. To allow the assessment of the possible influence of other established risk factors for venous thromboembolic and cardiovascular disease, 13 we also extracted data on healthcare encounters with a diagnosis of diabetes mellitus (either type 1 or type 2), atrial fibrillation, fractures or orthopedic procedures (surgery for fractures of the hip or leg, replacement arthroplasty, major trauma, hip and knee replacement, and fractures involving spinal cord injury), major surgery (abdominal surgery, cardiovascular surgery such as coronary artery bypass graft surgery, surgery for cancer, and gynecological surgery), and cancer (Table I in 
Statistical Analysis
Differences in baseline characteristics between subjects with non-O blood groups and those with blood group O were assessed with t tests for continuous variables and with χ 2 tests for categorical variables. In analyses of first occurrences (ie, incident cases) of VTEs or cardiovascular events, we followed up donors from the date of first electronically recorded blood donation during the study period until the date of first VTE or cardiovascular event, emigration, death, or end of follow-up (December 31, 2012), whichever came first. In the analyses of pregnancy/abortion-related venous thromboembolism, we terminated follow-up at 60 years of age. The main analyses for each outcome were run separately following up subjects only for a particular outcome of interest and not censoring for the occurrence of other outcomes. Therefore, subjects could have 1 event of each type. A person who was diagnosed with both pulmonary embolism and a deep venous thrombosis therefore contributed events in both of these outcome categories, as well as 1 event in the combined category for all venous thromboembolism. Realizing that the different types of outcomes share common risk factors, we also conducted sensitivity analyses in which follow-up was allowed only for the first event, regardless of the type. 14 We defined recurrent venous thromboembolism as deep vein thrombosis or pulmonary embolism, after any first recorded venous thrombotic event. During the follow-up period, these individuals were censored at date of emigration, death, or end of followup (December 31, 2012), whichever came first. Subjects with >1 venous event at first presentation (eg, both deep venous thrombosis and pulmonary embolism) were also included in the recurrence analyses. We only followed up subjects for the first recurrent event to avoid effects of lifelong antithrombotic prophylaxis, which is commonly used for repeat venous thrombosis. Because the patient registries do not specify diagnoses as incident or recurrent and because patients may have several healthcare contacts for the same thromboembolic event, we delayed the start of follow-up for recurrent thromboembolism until 180 days after the first healthcare contact for the first event.
We also considered the association between ABO blood group and the risk of provoked thromboembolic event, which was defined as occurring in an individual with at least 1 identifiable transient risk factor (trauma, fracture, major surgeries) no more than 6 months before any venous thrombotic event or a permanent risk factor (diabetes mellitus, cancer, atrial fibrillation) diagnosed any time before a thromboembolic event. 15 Baseline characteristics of continuous variables are presented as mean and SD and categorical variables as frequencies and percentages. The relative risk of VTEs or cardiovascular events in individuals with non-O blood groups compared with individuals with blood group O was expressed as incidence rate ratios (IRR), estimated with log-linear Poisson regression models. For each of the different outcomes, we fitted 2 separate models. Model 1 had adjustment for attained age (in 1-year intervals), sex, country (Sweden/Denmark), and calendar period of observation (in 1-year intervals). In model 2, we additionally adjusted for comorbidity. In both models, attained age and calendar period were treated as time-dependent factors, allowing individuals to move between categories over time, and were modeled as restricted cubic splines with 5 knots. We defined comorbidity as a history of a diagnosis of 1 of the following previously reported concomitant risk 16 major surgery, cancer, or fractures. Binary variables for each of these factors were included as timedependent variables in the model. Because atrial fibrillation might trigger thrombosis formation, increasing the risk of stroke, myocardial infarction, and arterial emboli, as well as being associated with risk of venous thromboembolism independently 17 or in association with concomitant stroke, 18 we additionally included atrial fibrillation in the comorbidity-adjusted model. Wald tests were used to compute 95% confidence intervals (CI). Interactions between blood group and sex, country, calendar period, age, and the respective comorbidities were individually tested. Because the observed IRRs did not differ materially between models 1 and 2, we present only estimates from model 2. We also tested for differences in risk among a subset of Swedish donors with known A1/ A2 subtypes compared with blood group O. Finally, we calculated the population-attributable risk percent (PAR%), that is, the percentage of events in the entire donor cohort that could be attributed to non-O blood groups. CIs for the PAR estimates were constructed with the substitution method. 19 All data processing and statistical analyses were done with SAS statistical analysis software (version 9.4, SAS Institute, Inc, Cary, NC). Values of P<0.05 were considered statistically significant.
Ethics
The creation of the SCANDAT2 database and the conduct of this study were approved by the regional ethics committees in Stockholm, Sweden, and the Danish Data Protection Agency in accordance with national legislations.
Results
A total of 1 112 072 blood donors were included in the analysis. Mean age at entry was 33 years. Median duration of follow-up was 12.6 years. Female donors constituted 51.4% (n= 571 840). Apart from differences in the proportion of Swedish/Danish donors (P<0.001) and immigrated donors (P<0.001), as well as of the distribution of Rhesus positivity (P<0.001), baseline demographics did not show any statistically significant difference between individuals with non-O and O blood groups ( Table 1) .
The analysis of incident VTEs and cardiovascular events included 665 952 individuals with non-O blood groups (A, B, or AB) and 446 120 with blood group O. Throughout followup, we observed 9170 VTEs and 24 653 cardiovascular events.
The IRRs were highest for the venous events, with all venous thrombotic events combined having an IRR of 1.80 (95% CI, 1.71-1.88) in individuals with non-O blood group compared with blood group O. The risk patterns were largely similar for pulmonary embolism and deep vein thrombosis, but a somewhat higher IRR was observed for pregnancy-related thromboembolic events (IRR, 2.22; 95% CI, 1.76-2.78). Among arterial events, IRRs were generally lower yet still statistically significant with IRRs of 1.10 (95% CI, 1.05-1.14) for myocardial infarction and 1.07 (95% CI, 1.02-1.12) for stroke in individuals in non-O blood groups compared with those in blood group O (Table 2) . Age demonstrated a significant interaction with ABO blood group (P<0.001 for all outcomes), with IRRs generally decreasing with older age (Table 2) . For all venous outcomes except other venous thrombosis, blood group also exhibited significant interactions with sex, with higher IRRs in men, although there was no evidence of interaction between blood group and sex for the arterial outcomes (Table II in the online-only Data Supplement). There was no evidence of statistical interaction between blood group and country (Table III in the online-only Data Supplement) or between blood group and calendar time (data not shown).
The PAR%s conferred by the non-O blood groups were considerably higher for VTEs than for the cardiovascular events, except for cerebrovascular stroke in young subjects and other arterial thrombosis. For venous vascular events, the PAR% ranged from 24% (95% CI, 14-34) for other venous thrombosis to 42% (95% CI, 31-52) for pregnancy/abortion-associated VTE. In addition, the PAR% was generally higher in younger subjects (Table 2) . Virtually identical results were reached in the sensitivity analyses in which we censored individuals upon having their first vascular event of any type (data not shown).
Further analyses of the 122 003 and 35 738 Swedish donors with known A1 and A2 subtype revealed increased risks of both venous and arterial events for individuals with the A1 subtype, whereas among individuals with the A2 subtype, significant risk was observed only for deep venous thrombosis (Table 3) . A consistent pattern was observed when the non-O blood group was subclassified as blood groups A, AB, and B, with the highest rate ratios for VTEs consistently seen in individuals with blood group AB and relatively lower risks observed with blood groups A and B compared with blood group O. The risk was slightly lower but statistically significant for arterial events compared with the venous group (Table IV in the online-only Data Supplement). Sensitivity analysis restricted to individuals with atrial fibrillation did not show any change in IRR estimates for acute myocardial infarction, stroke, and arterial embolic disease. Table 4 shows IRR estimates for recurrent and provoked pulmonary embolism and deep venous thrombosis. In both sets of analyses, the incidence was again higher in donors with non-O blood groups than in donors with blood group O, but relative risk estimates were generally lower than in the analyses of incident events. In individuals with non-O blood groups, the risks for recurrent pulmonary embolism (IRR, 1.47; 95% CI, 1.30-1.66) and deep venous thrombosis provoked by a comorbid illness (IRR, 1.67; 95% CI, 1.51-1.85) were higher compared with those with blood group O.
Finally, in analyses restricted to events associated with inpatient care (as opposed to inpatient and outpatient visits), the estimates remained largely similar, although the number of events decreased (data not shown).
Discussion
Using a large database comprising almost all Swedish and Danish blood donors in the past 2 decades, we were able to show that individuals with non-O blood groups are at increased risks of both venous thromboembolic and cardiovascular disease compared with individuals with blood group O. Strikingly, although IRRs were comparatively modest, the incidence differences translated to generally high PARs, exceeding 30% for VTEs in this healthy population of donors. Although absolute incidence rates were higher for recurrent and provoked venous events than for first-time events, the proportion attributable to the non-O blood group was smaller. This presumably may reflect a combination of the use of thromboprophylaxis after the first thromboembolic event and a greater prevalence of other important risk factors, with the latter explanation supported by higher absolute rates in both of these groups.
Our study has several important strengths. It is by far the largest study ever to have investigated the association between ABO blood group and risk of both venous thromboembolic and cardiovascular disease in a large, well-defined cohort with a wide age range and data on the most important comorbidities. The robust study design and complete followup data from nationwide population and health registers are additional strengths of the study. Because the blood group data were recorded prospectively in registers that are used in transfusion management, there should be little or no misclassification of blood group. Importantly, although blood donors may be aware of their blood group, it is unlikely that such knowledge will have any effect on behavior; therefore, significant confounding by lifestyle factors is unlikely.
At the same time, because the analyses are based on data on a healthy blood donor population, the results may not be entirely generalizable to other settings where comorbidity is more prevalent. This is exemplified by the lower relative risk estimates in the analysis of provoked venous thromboembolic disease and among older subjects. Similarly, because our study is limited to individuals of mostly European descent, it may be difficult to extrapolate our findings to other populations. This is especially relevant for the PAR calculations, which are affected by the prevalence of other risk factors. We also acknowledge that the SCANDAT2 database is based on administrative databases that were not created for research purposes. However, because these data are routinely used in clinical transfusion practice, the validity of the blood group data should be very high; therefore, we strongly believe that the blood group data are sufficiently accurate for this study purpose. The use of hospital registers for outcome ascertainment is likely to have resulted in some degree of underreporting and possibly some misclassification for the outcomes that do necessarily warrant hospital care or may remain undiagnosed, for example, deep venous thrombosis. However, the degree of such underreporting or misclassification is unlikely to be related to the donor blood group, which is a genetic factor, so it should affect only the power of investigation. Therefore, we do not believe that outcome misclassification would have an important effect on our observations, and it has previously been shown that the validity of VTEs and arterial events in the inpatient register has high positive predictive value. 20 The association between ABO blood group and the risk of vascular disease has long been recognized, but previous studies have usually been limited to specific hospital settings with marked variation in study quality. To the best of our knowledge, this is the first study to provide precise estimates of venous thrombosis and arterial disease risk with ABO blood groups using a large cohort of blood donors, and our results are consistent with previous reports. 3, [21] [22] [23] However, a recent meta-analysis reported higher relative risk estimates for both venous and arterial events compared with our study, although the included studies demonstrate a high degree of statistical heterogeneity. 4 Scattered hospital-based reports using small samples have previously shown inconsistent results attributable to ABO blood group on the risk of thromboembolic events after surgery, [24] [25] [26] trauma, 27, 28 cancer, 29, 30 and diabetes mellitus, 31 and these studies show a marked variation in study quality. The overall risk pattern observed in our study appeared to be similar for all subgroups of venous thromboembolic disease, with similar risk elevations for individuals with blood groups A and B who may be carriers of an O allele, and a uniformly higher risk for individuals with AB group who do not carry any O alleles. This pattern is compatible with the risk being correlated with the probability of carrying an O allele; however, because the SCANDAT 2 database does not include information on ABO genotyping, we can only speculate about the dose-response effect between the amount of O(H) antigen and risk of thromboembolism as reported previously. 32 Our observation of associations in both crude and comorbidity-adjusted analyses suggests that ABO blood groups act independently of other risk factors for thromboembolic and vascular events. The only significant interaction observed was that between age and blood group, and we believe that this is driven mostly by the gradually increasing baseline risk occurring with older age and is not necessarily reflective of a biological effect. The greater risk increase of both arterial and venous events seen in individuals with A1 subtype compared with those with A2 subtype indicates a greater hypercoagulable state for the A1 allele, presumably through higher levels of von Willebrand factor and factor VIII compared with other genotypes. 33, 34 We would like to caution interpretations on 2 specific associations. The effect conferred by blood group B on other VTEs seems most likely to be related to the relatively small sample sizes and the heterogeneous mixture of several minor venous thrombosis categories, which might reflect some residual confounding from specific comorbidities related to ABO blood group, for example, cancer. The relatively smaller magnitude of our relative risk estimates for incident and recurrent events compared with previous studies 29, 35 might be attributed to the fact that we were not able to exclude individuals on anticoagulation therapy. In addition, our criteria for identifying subjects with a diagnosis of recurrent thromboembolic event could have led to missing early recurrent thrombosis cases and misclassifying care for the already prevalent thrombosis as new events. However, again, we believe that such misclassification is unlikely to relate to the donors' blood group, making it less likely to affect the risk estimates. That said, if prevalent thrombosis was often misclassified as a recurrent event, this may have contributed to the generally lower relative risk estimates for recurrent thrombosis. Nevertheless, the risk estimates in our study suggest that in the absence of ultrasound or D-dimer measurement, non-O blood groups may still potentially benefit as a simple proxy biomarker in the assessment and planning of anticoagulation therapy for residual venous thrombosis.
Possible mechanisms underlying the ABOthromboembolism association include excess concentrations of or interaction with factor VIII and von Willebrand factor in individuals with non-O blood 36, 37 ; a unified action of immunedominant blood group antigens present in the lining endothelium of blood vessels, along with the production of von Willebrand factor by the endothelial cells 38, 39 ; and genetic variation in the ABO locus, affecting serum levels of inflammatory markers such as soluble intracellular adhesion molecule 1, 40 tumor necrosis factor, 41 and soluble E-and P-selectin.
42,43
Conclusions
Our study provides robust evidence of a consistent association between the non-O blood groups and both VTEs and cardiovascular events, with uniformly greater risk for venous events. Given that non-O blood groups confer an overall increased risk of incident, recurrent, and provoked thromboembolism, ABO blood group may have a role in thrombosis risk assessment and could potentially be added to available clinical prediction systems, given the relative ease and robustness of assessing blood group phenotypes and lack of
